tetano
Editor, Senior Moderator
Anal Bioanal Chem
. 2021 May 18.
doi: 10.1007/s00216-021-03377-6. Online ahead of print.
Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects
Yousef Rasmi[SUP] 1 2 [/SUP], Xiaokang Li[SUP] 3 4 [/SUP], Johra Khan[SUP] 5 [/SUP], Tugba Ozer[SUP] 6 [/SUP], Jane Ru Choi[SUP] 7 8 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) pandemic is currently a serious global health threat. While conventional laboratory tests such as quantitative real-time polymerase chain reaction (qPCR), serology tests, and chest computerized tomography (CT) scan allow diagnosis of COVID-19, these tests are time-consuming and laborious, and are limited in resource-limited settings or developing countries. Point-of-care (POC) biosensors such as chip-based and paper-based biosensors are typically rapid, portable, cost-effective, and user-friendly, which can be used for COVID-19 in remote settings. The escalating demand for rapid diagnosis of COVID-19 presents a strong need for a timely and comprehensive review on the POC biosensors for COVID-19 that meet ASSURED criteria: Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end users. In the present review, we discuss the importance of rapid and early diagnosis of COVID-19 and pathogenesis of COVID-19 along with the key diagnostic biomarkers. We critically review the most recent advances in POC biosensors which show great promise for the detection of COVID-19 based on three main categories: chip-based biosensors, paper-based biosensors, and other biosensors. We subsequently discuss the key benefits of these biosensors and their use for the detection of antigen, antibody, and viral nucleic acids. The commercial POC biosensors for COVID-19 are critically compared. Finally, we discuss the key challenges and future perspectives of developing emerging POC biosensors for COVID-19. This review would be very useful for guiding strategies for developing and commercializing rapid POC tests to manage the spread of infections.Graphical abstract.
Keywords: COVID-19; Chip-based biosensors; Commercialization; Diagnostic biomarkers; Paper-based biosensors; Point-of-care biosensors.
. 2021 May 18.
doi: 10.1007/s00216-021-03377-6. Online ahead of print.
Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects
Yousef Rasmi[SUP] 1 2 [/SUP], Xiaokang Li[SUP] 3 4 [/SUP], Johra Khan[SUP] 5 [/SUP], Tugba Ozer[SUP] 6 [/SUP], Jane Ru Choi[SUP] 7 8 [/SUP]
Affiliations
- PMID: 34008124
- DOI: 10.1007/s00216-021-03377-6
Abstract
Coronavirus disease 2019 (COVID-19) pandemic is currently a serious global health threat. While conventional laboratory tests such as quantitative real-time polymerase chain reaction (qPCR), serology tests, and chest computerized tomography (CT) scan allow diagnosis of COVID-19, these tests are time-consuming and laborious, and are limited in resource-limited settings or developing countries. Point-of-care (POC) biosensors such as chip-based and paper-based biosensors are typically rapid, portable, cost-effective, and user-friendly, which can be used for COVID-19 in remote settings. The escalating demand for rapid diagnosis of COVID-19 presents a strong need for a timely and comprehensive review on the POC biosensors for COVID-19 that meet ASSURED criteria: Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end users. In the present review, we discuss the importance of rapid and early diagnosis of COVID-19 and pathogenesis of COVID-19 along with the key diagnostic biomarkers. We critically review the most recent advances in POC biosensors which show great promise for the detection of COVID-19 based on three main categories: chip-based biosensors, paper-based biosensors, and other biosensors. We subsequently discuss the key benefits of these biosensors and their use for the detection of antigen, antibody, and viral nucleic acids. The commercial POC biosensors for COVID-19 are critically compared. Finally, we discuss the key challenges and future perspectives of developing emerging POC biosensors for COVID-19. This review would be very useful for guiding strategies for developing and commercializing rapid POC tests to manage the spread of infections.Graphical abstract.
Keywords: COVID-19; Chip-based biosensors; Commercialization; Diagnostic biomarkers; Paper-based biosensors; Point-of-care biosensors.